Leveraging mRNA Sequences for helping host to have antibody

Scientists manipulated a natural cellular process to ramp up levels of two proteins used by the virus to infect other cells, packaged the protein-boosting instructions in nanoparticles and injected them into mice. Within a month, the mice had developed antibodies against the SARS-CoV-2 virus.

The technique involves altering specific sequences of messenger RNA, molecules that translate genetic information into functional proteins. While these sequences are not translated to proteins, the researchers changed their structures to promote higher-than-usual levels of proteins. The sequences are known as untranslated regions, or UTRs.

"For now, it's a proof of concept—we've demonstrated we can optimize a sequence of messenger RNA to improve protein production, produce antigens and induce antibodies against those specific antigens."

The crux of the method is typical to vaccine development: using snippets of a pathogen's structure to produce an antigen—the foreign substance that triggers an appropriate immune response—and finding a safe way to introduce it to the body.

But the engineering technique takes antigen design to a new level by making use of messenger RNA UTRs, Dong said.

His lab worked with the two UTRs that bookend the start and finish of protein assembly, functioning as regulators of that process and influencing how the resulting protein interacts with others. UTRs themselves are strings of nucleotides, the molecules that compose RNA and DNA.

"For our application we tried to optimize the UTRs to improve the protein production process. We wanted as much protein produced as possible—so we can give a small dose of messenger RNA that produces enough antigen to induce antibodies against the virus," Dong said.

The team experimented with two potential antigens that the novel coronavirus is known to use to cause infection: a spike protein on its surface and a receptor binding domain, a component of the spike protein, that the virus uses to make its way into host cells—a necessary step to make copies of itself. Both are used in other SARS-CoV-2 vaccine candidates.

After manipulating the messenger RNA for these two proteins, the team encased them in lipid nanoparticles developed previously in Dong's lab. They injected mice with the experimental vaccine and gave them a booster two weeks later. A month after the first injection, immune cells in the mice had taken up the antigens of the two proteins and developed antibodies against them.

"It takes some time for the immune system to process the antigens and have cells produce antibodies,"

 

nano-particle로 뭐 하는 건가 싶었는데, 그건 아니다. mRNA의 양 끝에 있는 UTR 염기서열을 최적화 하여 Antigen을 encoding하고 있는 mRNA를 만든 뒤, 이것을 lipid로 만든 exosome에 담아서 이것을 넣으면 Antibody를 많이 만들 수 있게 해준다는 내용이다. 

 

reference

Chunxi Zeng et al, Leveraging mRNA Sequences and Nanoparticles to Deliver SARS‐CoV‐2 Antigens In Vivo, Advanced Materials (2020). DOI: 10.1002/adma.202004452